Date: 2012-10-15
Type of information: Services contract
Compound: PolyPEG®
Company: PolyTherics (UK) undisclosed top five pharmaceutical company
Therapeutic area:
Type agreement: services
Action mechanism: PolyPEG™ is a patented polymer designed to extend the half-life in the body of therapeutic proteins to which it is conjugated. It consists of poly(ethylene) glycol (PEG) ‘teeth’ along a polymer backbone to create a comb-shaped format. The format of PolyPEG™ provides a conjugated protein with a lower viscosity than would generally be possible with an equivalent sized linear PEG. This is particularly useful when a protein has to be administered at high concentration and can enable the use of standard gauge needles for injection.
Disease:
Details: PolyTherics, a provider of solutions to enable the development of better biopharmaceuticals, has extended its collaboration with a top five pharmaceutical company to further investigate applications of PolyTherics’ polymer, PolyPEG®. Under the terms of the collaboration, the properties of several different proteins will be evaluated following conjugation to a range of PolyPEG® polymers of different molecular architectures. The evaluations will include in vitro binding and activity assays with proteins targeted to a number of disease areas. Selected PolyPEG® protein conjugates will also be evaluated in imaging and pharmacokinetic studies.
Financial terms:
Latest news:
